NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$105.99 +3.73 (+3.65 %)
(As of 12/10/2018 04:00 PM ET)
Previous Close$102.26
Today's Range$100.68 - $106.9750
52-Week Range$51.05 - $133.74
Volume355,705 shs
Average Volume653,581 shs
Market Capitalization$3.03 billion
P/E Ratio-7.37
Dividend YieldN/A
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:ICPT
Previous Symbol


Debt-to-Equity Ratio3.83
Current Ratio5.98
Quick Ratio5.98


Trailing P/E Ratio-7.37
Forward P/E Ratio-10.24
P/E GrowthN/A

Sales & Book Value

Annual Sales$130.96 million
Price / Sales24.00
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.65 per share
Price / Book163.06


EPS (Most Recent Fiscal Year)($14.38)
Net Income$-360,360,000.00
Net Margins-202.93%
Return on Equity-645.54%
Return on Assets-65.34%


Outstanding Shares29,650,000
Market Cap$3.03 billion

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) released its quarterly earnings data on Wednesday, October, 31st. The biopharmaceutical company reported ($2.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.65) by $0.47. The biopharmaceutical company earned $47 million during the quarter, compared to analysts' expectations of $48.24 million. Intercept Pharmaceuticals had a negative return on equity of 645.54% and a negative net margin of 202.93%. The business's revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter last year, the firm earned ($2.89) earnings per share. View Intercept Pharmaceuticals' Earnings History.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Intercept Pharmaceuticals.

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals updated its FY 2018 earnings guidance on Wednesday, October, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $170-185 million, compared to the consensus revenue estimate of $181.84 million.

What price target have analysts set for ICPT?

18 equities research analysts have issued twelve-month price objectives for Intercept Pharmaceuticals' shares. Their forecasts range from $57.00 to $253.00. On average, they anticipate Intercept Pharmaceuticals' share price to reach $150.40 in the next twelve months. This suggests a possible upside of 41.9% from the stock's current price. View Analyst Price Targets for Intercept Pharmaceuticals.

What is the consensus analysts' recommendation for Intercept Pharmaceuticals?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Intercept got a significant boost with the approval of Ocaliva for the treatment of PBC.  Although sales had earlier taken a hit due to the safety issues regarding Ocaliva, management’s efforts to increase awareness about the updated level and promote Ocaliva, thereafter, is reaping results. Solid growth in new patient enrollment in the third-quarter should lead to stronger sales in the fourth quarter. Moreover, the company is looking to expand the drug’s label in the promising NASH  and PSC space. The phase III NASH program includes the REGENERATE trial among patients with advanced liver fibrosis and the REVERSE trial among patients with compensated cirrhosis. Results from the REGENERATE trial are expected in the first half of 2019. However, we are concerned about the lack of other late-stage candidates in the company’s pipeline. Shares have outperformed the industry in the year so far." (12/10/2018)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $170 12-month price target. We think Elafibranor Ph2 PBC data from Genfit (GNFT.PA, Not covered) looks competitive among Ph2 assets but we do not view today’s update as a near or mid-term threat to ICPT’s OCA. Elafibranor Ph2 looks broadly similar to recently updated Sedalapar data (for 52-week analysis) from Cymabay (CBAY, OW E. Merle) which is not surprising as both are PPAR agonists, but detailed full data could be helpful in comparing the efficacy and safety profiles of these assets. We think pivotal PBC trial enrollment will take time before either asset would pose a commercial threat to OCA in PBC. We remain focused on REGENERATE readout in NASH for ICPT in 1H 2019." (12/6/2018)
  • 3. Needham & Company LLC analysts commented, "Intercept reported $34.5M in U.S. Ocaliva sales (+21% q/q; +24% y/y), slightly above our $34.0M and consensus $32M ests. WW sales were $43.2M, above our $43.0M and consensus $41M ests. Sales growth driven primarily by increased volume w/ early adopter prescriber base. Company expects some weakness in 3Q18 (summer), but reiterated 2018 WW sales guidance of $170-$185M. Phase 3 NASH timelines are unch, w/ REGENERATE trial results still expected 1H19. We are biased towards a positive outcome. Maintain HOLD given key milestone is in 2019." (8/2/2018)

Has Intercept Pharmaceuticals been receiving favorable news coverage?

News headlines about ICPT stock have trended very positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Intercept Pharmaceuticals earned a daily sentiment score of 3.9 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.

Who are some of Intercept Pharmaceuticals' key competitors?

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:
  • Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 50)
  • Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 48)
  • Mr. Jerome B. Durso, Chief Operating Officer (Age 50)
  • Mr. David Ford, Chief HR Officer (Age 49)
  • Dr. David Shapiro, Chief Medical Officer (Age 64)

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (14.96%), Vanguard Group Inc. (6.59%), First Trust Advisors LP (3.69%), Deutsche Bank AG (1.48%), Sarissa Capital Management LP (0.87%) and Elk Creek Partners LLC (0.79%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim, Sandip Kapadia and SPA Genextra. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Which major investors are selling Intercept Pharmaceuticals stock?

ICPT stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Sarissa Capital Management LP, Elk Creek Partners LLC, Alliancebernstein L.P., Peregrine Capital Management LLC, Pinnacle Associates Ltd., TIAA CREF Investment Management LLC and Fisher Asset Management LLC. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, David Shapiro, Lisa Bright, Mark Pruzanski and SPA Genextra. View Insider Buying and Selling for Intercept Pharmaceuticals.

Which major investors are buying Intercept Pharmaceuticals stock?

ICPT stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Marshall Wace North America L.P., Deutsche Bank AG, Vanguard Group Inc., Biondo Investment Advisors LLC, AXA, American Century Companies Inc. and AQR Capital Management LLC. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener and Mark Pruzanski. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $105.99.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $3.03 billion and generates $130.96 million in revenue each year. The biopharmaceutical company earns $-360,360,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Intercept Pharmaceuticals employs 507 workers across the globe.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]

MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  867 (Vote Outperform)
Underperform Votes:  470 (Vote Underperform)
Total Votes:  1,337
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel